Alvotech hefur klíníska rannsókn á AVT16, fyrirhugaðri líftæknilyfjahliðstæðu við Entyvio
September 25, 2024 05:01 ET
|
Alvotech
Alvotech er einn tveggja aðila sem vitað er að hafi byrjað klíníska rannsókn á sjúklingum fyrir fyrirhugaða líftæknilyfjahliðstæðu við Entyvio (vedolizumab)Á síðustu tólf mánuðum, fram til loka...
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
September 25, 2024 05:01 ET
|
Alvotech
Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
September 25, 2024 05:00 ET
|
Alvotech
Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...
Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley
August 26, 2024 09:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt í 22. árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanleys í New York. Fulltrúar framkvæmdastjórnar félagsins munu meðal annars sitja fyrir svörum...
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 09:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd...
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 09:14 ET
|
Alvotech
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins
August 15, 2024 16:15 ET
|
Alvotech
Heildartekjur voru 236 milljónir dollara á fyrri helmingi ársins, sem er meira en tíföldun frá sama tímabili í fyrraTekjur af vörusölu á fyrri helmingi ársins jukust um 190% frá sama tímabili í fyrra...
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
August 15, 2024 16:15 ET
|
Alvotech
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190%...
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
August 15, 2024 16:15 ET
|
Alvotech
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...